| Literature DB >> 29534053 |
Giada Acciaroli1, Martina Vettoretti2, Andrea Facchinetti3, Giovanni Sparacino4.
Abstract
Minimally invasive continuous glucose monitoring (CGM) sensors are wearable medical devices that provide real-time measurement of subcutaneous glucose concentration. This can be of great help in the daily management of diabetes. Most of the commercially available CGM devices have a wire-based sensor, usually placed in the subcutaneous tissue, which measures a "raw" current signal via a glucose-oxidase electrochemical reaction. This electrical signal needs to be translated in real-time to glucose concentration through a calibration process. For such a scope, the first commercialized CGM sensors implemented simple linear regression techniques to fit reference glucose concentration measurements periodically collected by fingerprick. On the one hand, these simple linear techniques required several calibrations per day, with the consequent patient's discomfort. On the other, only a limited accuracy was achieved. This stimulated researchers to propose, over the last decade, more sophisticated algorithms to calibrate CGM sensors, resorting to suitable signal processing, modelling, and machine-learning techniques. This review paper will first contextualize and describe the calibration problem and its implementation in the first generation of CGM sensors, and then present the most recently-proposed calibration algorithms, with a perspective on how these new techniques can influence future CGM products in terms of accuracy improvement and calibration reduction.Entities:
Keywords: calibration; continuous glucose monitoring; diabetes; glucose sensors
Mesh:
Substances:
Year: 2018 PMID: 29534053 PMCID: PMC5872072 DOI: 10.3390/bios8010024
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Figure 1Representative three days of blood glucose (BG) monitoring obtained with self-monitoring BG (SMBG), diamonds, and with continuous glucose monitoring (CGM), continuous line. Horizontal dashed lines indicate the euglycemic range. Data taken from a previously published study [15].
Figure 2Examples in which the continuous glucose monitoring (CGM) sensor output (continuous line) (a) overestimates and (b) underestimates the reference blood glucose (BG) (points). Data taken from a previously published study [15].
Figure 3(a) Two-compartment model describing the blood glucose to interstitial glucose (BG-to-IG) kinetics. is the rate of appearance; are rate constants. The time constant of the BG-to-IG system is . (b) Representative blood glucose (BG) (dashed line) and interstitial glucose (IG) (continuous line) concentration profiles simulated as described in the text assuming τ = 11 min.
Figure 4Representative raw CGM sensor signal (continuous line, units not specified by the manufacturer) that exhibits a nonphysiological drift (dashed line) due to the time-variability of sensor sensitivity. Data were previously published in [15].
Summary of the reviewed calibration techniques.
| Study | Calibration Technique | Model of BG-IG Dynamic | Real-Time Use in Wearable Devices | Calibrations per Day | Validation Data | Improvements Compared to Manufacturer (if Applicable) |
|---|---|---|---|---|---|---|
| Aussedat et al. [ | Linear regression with feature to detect phases of steady state signal | No, but use of heuristic technique | Yes | Not specified | Real data from a miniaturized glucose sensor used in rats | / |
| Knobbe et al. [ | Extended Kalman filter | Yes | Yes | Not specified | Real data from the Medronic (Northridge, CA, USA) MiniMed CGM system | / |
| Kuure-Kinsey et al. [ | Dual rate Kalman filter | No | Yes | 3 | Synthetic data; data from an experimental glucose sensor used in rats | / |
| Facchinetti et al. [ | Extended Kalman filter | Yes | Yes | 4 | Synthetic data | / |
| Leal et al. [ | Auto-regressive models | No | Yes | At least 3 | Real data from the Medtronic (Northridge, CA, USA) MiniMed CGMS system gold | Median RAD 1 decreased of 4.6% |
| Leal et al. [ | Linear regression | No | No | At least 3 | Real data from the Medtronic (Northridge, CA, USA) MiniMed CGMS system gold | Median RAD 1 decreased of 2% |
| Barceló-Rico [ | Multiple local dynamic models [ | Yes | Yes | 3–4 | Real data from the GlucoDay (Menarini, Florence, Italy) sensor [ | MARD 2 decreased of 3.9% in [ |
| Mahmoudi et al. [ | Rate-limiting filtering, selective smoothing, and robust regression | No, but use of heuristic technique | Yes | Maximum 4 | Real data from SCGM 1 (Roche Diagnostic, Mannheim, Germany) system | / |
| Kirchsteiger et al. [ | Linear matrix inequalities | Yes | Yes | Roughly 6 (more in day 1) | Real data from the FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA, USA) system | MARD 2 decreased of about 4.7% [ |
| Guerra et al. [ | Linear regression and regularized deconvolution | Yes | Yes | 2 | Synthetic data; real data from the FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA, USA) and DexCom Seven Plus (Dexcom Inc., San Diego, CA, USA) systems | RMSE 3 decreased of 7.2 mg/dL |
| Vettoretti et al. [ | Linear regression and regularized deconvolution | Yes | Yes | 2 | Real data from the Dexcom G4 Platinum (Dexcom Inc., San Diego, CA, USA) system | MARD 2 decreased of 1.2% |
| Acciaroli et al. [ | Linear regression and regularized deconvolution | Yes | Yes | 1 | Real data from the Dexcom G4 Platinum (Dexcom Inc., San Diego, CA, USA) system | MARD 2 decreased of 1.2%, calibrations reduced from 2 to 1 per day |
| Acciaroli et al. [ | Multiple-day model and regularized deconvolution | Yes | Yes | 0.25 in [ | Real data from the Dexcom G4 Platinum (Dexcom Inc., San Diego, CA, USA) system [ | MARD 2 decreased of 1.2%, calibrations reduced from 2 to 0.25 per day [ |
| Lee et al. [ | Linear regression with run-to-run | No | Yes, after a few weeks of CGM use | 2 | Synthetic data | / |
| Zavitsanou et al. [ | Linear regression with weakly updating feature | No | Yes, after a few weeks of CGM use | 2 | Real data from the Dexcom G4 Platinum (Dexcom Inc., San Diego, CA, USA) system | / |
| Del Favero et al. [ | Linear regression and regularized constrained deconvolution | Yes | No | 13 in [ | Real data from the DexCom Seven Plus [ | MARD 2 decreased of 6.9% in [ |
1 RAD, relative absolute difference; 2 MARD, mean absolute relative difference; 3 RMSE, root mean square error.